EAU 2013 - Programme Book - YouMed

Sunday, 17 March - EAU Programme
Abstract Session
15.45 - 17.15 Androgen deprivation therapy, still to improve..
Yellow Hall 1-2-3 - Level N1
Poster Session 56
Chairs: F. Calais Da Silva Junior, Lisbon (PT)
L.N. Türkeri, Istanbul (TR)
Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes
in length, followed by 2 minutes for discussion. Extended presentations (*) are 4 minutes in length, followed
by 2 minutes for discussion.
* 674 Enzalutamide monotherapy: Results from a phase 2 study in hormone naive prostate cancer patients
B. Tombal, M. Borre, P. Rathenborg, P. Werbrouck, A. Heidenreich, P. Iversen, E. Baskin-Bey, F. Perabo,
D. Phung, M.R. Smith (Brussel, Kortrijk, Belgium; Skejby, Herlev, Copenhagen, Denmark; North-Rhine
Westphalia, Germany; Staines, United Kingdom; Northbrook, Boston, United States of America; Leiderdorp,
The Netherlands)
* 675 Survival and metastases among non-metastatic prostate cancer patients treated with androgen
deprivation therapy (ADT) in Denmark, 1997-2010
M. Nguyen-Nielsen, M.L. Maegbaek, R.K. Hernandez, H.T. Sørensen, V. Ehrenstein, A. Liede (Århus,
Denmark; Thousand Oaks, South San Francisco, United States of America)
676 Polymorphisms of androgen transporting gene SLCO2B1 may participate in hormone-resistance and ethnic
difference in response to androgen deprivation therapy
N. Fujimoto, T. Kubo, H. Bui, T. Yoshida, T. Matsumoto (Kitakyushu, Japan)
677 Lower risk of cardiovascular (CV) events and death in men receiving ADT by gonadotropin releasing
hormone (GnRH) antagonist, degarelix, compared with luteinising hormone-releasing (LHRH) agonists
B. Tombal, P. Albertsen, A. De La Taille, E. Van Der Meulen, B-E. Persson, T.K. Olesen, J. Nilsson (Brussels,
Belgium; Farmington, United States of America; Paris, France; Copenhagen, Denmark; St Prex, Switzerland;
Lund, Sweden)
678 Disease control-related outcomes from an analysis of six comparative randomised clinical trials of
degarelix versus luteinising hormone-releasing hormone (LHRH) agonists
K. Miller, E.D. Crawford, N. Shore, C. Karup, E. Van Der Meulen, B-E. Persson (Berlin, Germany; Aurora,
Myrtle Beach, United States of America; Copenhagen, Denmark; St Prex, Switzerland)
679 PSA patterns during off-time treatment period in patients undergoing intermittent androgen deprivation.
Is PSA doubling time reliable in every case?
R.E. Sanchez Salas, D. Prapotnich, F. Olivier, M. Fhima, P. Descamps, S. David, F. Secin, E. Barret,
M. Galiano, F. Rozet, X. Cathelineau (Paris, France; Buenos Aires, Argentina)
680 Intermittent versus continuous cyproterone acetate in bone metastatic prostate cancer: Results of a
randomized trial
P.C.M.S. Verhagen, M.F. Wildhagen, A.M. Verkerk, W.A.B.M. Bolle, E. Vjaters, H. Pagi, L. Kukk, D. Bratus,
R. Fiala, C.H. Bangma, F.H. Schröder, G.H. Mickisch (Rotterdam, The Netherlands; Riga, Latvia; Tallinn,
Estonia; Maribor, Slovenia; Olomouc, Czech Republic; Bremen, Germany)
681 Correlation between information provided by urologists and messages understood by patients when
starting androgen blockade for advanced prostate cancer
T. Lebret, B. Duclos-Morlaes, D. Comet, S. Droupy (Suresnes, Levallois-Perret, Nanterre, Nîmes, France)
EAU Milan 2013
229
Sunday